Provided by Tiger Trade Technology Pte. Ltd.

CINGULATE INC.

5.55
+0.22004.13%
Post-market: 5.50-0.0489-0.88%19:30 EDT
Volume:234.69K
Turnover:1.28M
Market Cap:80.71M
PE:-1.56
High:5.55
Open:5.35
Low:5.18
Close:5.33
52wk High:11.89
52wk Low:3.16
Shares:14.54M
Float Shares:14.11M
Volume Ratio:1.67
T/O Rate:1.66%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.5600
EPS(LYR):-4.4408
ROE:-198.74%
ROA:-66.94%
PB:3.44
PE(LYR):-1.25

Loading ...

U.S. Research Roundup-Amgen, Analog Devices, Moderna

Reuters
·
Aug 20

Cingulate Inc : Ascendiant Capital Markets Cuts Target Price to $44 from $52

THOMSON REUTERS
·
Aug 20

Maxim Group Keeps Their Buy Rating on Cingulate Inc (CING)

TIPRANKS
·
Aug 14

Cingulate Q2 EPS $(0.45) Beats $(0.63) Estimate

Benzinga Earnings
·
Aug 13

Press Release: Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness

Dow Jones
·
Aug 13

Cingulate publishes peer-reviewed data on CTx-1301 pharmacokinetic profile

TIPRANKS
·
Aug 11

Cingulate Publishes Peer-Reviewed Pharmacokinetic Study of ADHD Candidate CTx-1301 in CNS Drugs

Reuters
·
Aug 11

Cingulate Publishes Peer-Reviewed Data Demonstrating CTx-1301’s Differentiated Pharmacokinetic Profile

GlobeNewswire
·
Aug 11

Cingulate Phase 3 ADHD Trial Results for CTx-1301 Published in Journal of Child and Adolescent Psychopharmacology

Reuters
·
Jul 30

Cingulate - Ctx-1301 Shows Statistically Significant Improvements over Placebo in Phase 3 Primary Endpoint

THOMSON REUTERS
·
Jul 30

Cingulate Announces Publication of Phase 3 Adhd Trial Results in Journal of Child and Adolescent Psychopharmacology

THOMSON REUTERS
·
Jul 30

Cingulate Restructures Leadership, Eliminates Chief Legal Officer

TIPRANKS
·
Jul 24

Cingulate Eliminates Chief Legal Officer Role, Nilay Patel to Depart Aug. 3

Reuters
·
Jul 24

Cingulate enhances equity plan and updates board leadership

TIPRANKS
·
Jul 15

Cingulate Inc Added to Broad Russell 3000E Index

TIPRANKS
·
Jul 02

Cingulate Inc. (NASDAQ: CING) Added to Russell 3000E®

GlobeNewswire
·
Jul 02

Cingulate issues patent by USPTO for CTx-1301

TIPRANKS
·
Jun 16

Cingulate wins first US patent for ADHD drug CTx-1301, exclusivity to December 2042

Reuters
·
Jun 16

Cingulate director Jeff Hargroves acquires 97,276 common shares for $490,271.04

Reuters
·
Jun 09

Cingulate files Form 3 initial beneficial ownership statement for director Jeff Hargroves

Reuters
·
Jun 09